ArticleArthritis research & therapy2011
Risk factors for ANA positivity in healthy persons.
Article in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Frequency of extractable nuclear antigen seropositivity among individuals seronegative for antinuclear antibodies on indirect immunofluorescence: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Prevalence of coeliac disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Lupus science & medicine · 2024Pooled it
- Pooled it
- Pooled it
- Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.The Journal of allergy and clinical immunology · 2020Trial
- Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.The Journal of rheumatology · 2017Trial
- Prevalence and correlates of antinuclear antibodies in a Japanese community sample: a cross-sectional study.Current therapeutic research, clinical and experimental · 2026Article
- Systemic Lupus Erythematosus and the Risk of Coeliac Disease: Substantial Discrepancies Among Studies Highlight a Significant Research Gap.Mediterranean journal of rheumatology · 2026Review
- A Novel Mechanism for Autoantigenicity: Condensate Conformational Change.Biomolecules · 2026Article
- Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease.Arthritis care & research · 2026Article
- [Inflammatory rheumatic diseases in patients with post-COVID syndrome].Zeitschrift fur Rheumatologie · 2026Article
- Prognostic value of longitudinal antinuclear antibody dynamics in rheumatoid arthritis: a retrospective cohort study.Frontiers in immunology · 2026Article
- Differences in IgG Sialylation Distinguish Asymptomatic From Symptomatic Antinuclear Antibody-Positive Individuals.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors.Scientific reports · 2025Article
- Identification of STAT3 signaling as a shared pathogenic signature in systemic lupus erythematosus, chronic obstructive pulmonary disease, and asthma.Scientific reports · 2025Article
- Article
- Identification of Biomarkers Co-Associated with Lactylation and Acetylation in Systemic Lupus Erythematosus.Biomedicines · 2025Article
- Sex-specific associations between systemic autoantibodies and allergic sensitization or allergic disease - results from a population-based study.Frontiers in immunology · 2025Article
- Ancestry-based differences in the immune phenotype are associated with lupus activity.JCI insight · 2023Article
- Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease.BMC rheumatology · 2023Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe finding of antinuclear antibody (ANA) positivity in a healthy individual is usually of unknown significance and in most cases is benign. However, a subset of such individuals is at risk for development of autoimmune disease. We examined demographic and immunological features that are associated with ANA positivity in clinically healthy persons to develop insights into when this marker carries risk of progression to lupus.
methodsBiological samples from healthy individuals and patients with systemic lupus erythematosus (SLE) were obtained from the Dallas Regional Autoimmune Disease Registry (DRADR). Measurements carried out on serum samples included ANA, extractable nuclear antibodies (ENA) and autoantibody profiling using an array with more than 100 specificities. Whole blood RNA samples from a subset of individuals were used to analyze gene expression on the Illumina platform. Data were analyzed for associations of high ANA levels with demographic features, the presence of other autoantibodies and with gene expression profiles.
resultsOverall, ANA levels are significantly higher in females than in males and this association holds in patients with the autoimmune diseases lupus and rheumatoid arthritis (RA) as well as in healthy controls (HC). Age was not significantly associated with ANA levels and the elevated ANA values could not be explained by higher IgG levels. Another autoantibody, anti- cyclic citrullinated peptide (CCP), did not show gender dimorphism in rheumatoid arthritis (RA) or healthy individuals. The autoantigen array showed significant elevations of other autoantibodies in high ANA HCs. Some of these autoantibodies were directed to antigens in skin and others were related to autoimmune conditions of kidney, thyroid or joints. Gene expression analyses showed a greater prevalence of significantly upregulated genes in HCs with negative ANA values than in those with significant ANA positivity. Genes upregulated in high ANA HCs included a celiac disease autoantigen and some components of the Type I interferon (IFN) gene signature.
conclusionsRisks for ANA positivity include female gender and organ-specific autoimmunity. Upregulation of skin-specific autoantibodies may indicate that early events in the break of tolerance take place in cutaneous structures. Some of these changes may be mediated by Type I IFN. Blood profiling for expressed autoantibodies and genes has the potential to identify individuals at risk for development of autoimmune diseases including lupus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.